Fig. 3

Effect of GSK-343 on dopamine pathway. MPTP mice showed a significant decrease of DAT expression in substantia nigra (B, B1, score F) compared to the Sham group (A, A1, score F). GSK-343 administration, at the doses of 5 mg/kg (D, D1, score F) and more effectively at the dose of 10 mg/kg (E, E1, score F) increased DAT-positive cells compared to MPTP mice. GSK-343 1 mg/kg did not demonstrate significant neuroprotection (C, C1, score F). MPTP-injected animals exhibited a considerable loss of dopamine and its metabolites, compared to the Sham mice; contrarily, treatment with GSK-343 at the doses of 5 mg/kg and 10 mg/kg increased metabolites levels (G–I). Data are representative of at least three independent experiments. Values are means ± SEM. One-way ANOVA test. ***p < 0.001 vs Sham; ###p < 0.001 vs MPTP